Amphiphilic peptides can aid the delivery of CRISPR ribonucleoproteins into primary human lymphocytes at low toxicity, boosting editing yields with respect to the use of electroporation.
This is a preview of subscription content, log in via an institution to check access.
References
Irvine, D. J., Maus, M. V., Mooney, D. J. & Wong, W. W. Science 378, 853–858 (2022).
Maude, S. L. et al. N. Engl. J. Med. 371, 1507–1517 (2014).
Jinek, M. et al. Science 337, 816–821 (2012).
Stadtmauer, E. A. et al. Science 367, eaba7365 (2020).
Georgiadis, C. et al. Leukemia 35, 3466–3481 (2021).
Eyquem, J. et al. Nature 543, 113–117 (2017).
Roth, T. L. et al. Nature 559, 405–409 (2018).
Schober, K. et al. Nat. Biomed. Eng. 3, 974–984 (2019).
Foss, D. V. et al. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-023-01032-2 (2023).
Gaudelli, N. M. et al. Nature 551, 464–471 (2017).
Webber, B. R. et al. Nat. Commun. 10, 5222 (2019).
Rurik, J. G. et al. Science 375, 91–96 (2022).
Banskota, S. et al. Cell 185, 250–265.e16 (2022).
Hamilton, J. R. et al. Cell Rep. 35, 109207 (2021).
Kreitz, J. et al. Nature 616, 357–364 (2023).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.G. is a co-inventor on various patent applications filed by Mass General Brigham and the Massachusetts General Hospital on gene-editing technologies. J.G. is a paid consultant for Poseida Therapeutics, a company developing various gene and cell therapies, including CAR T cell therapies and delivery modalities, and has financial interests in the company. A.S. is a contributor to patents related to CAR T cells.
Rights and permissions
About this article
Cite this article
Grünewald, J., Schmidts, A. A gentler yield of ex vivo-edited T cells. Nat. Biomed. Eng 7, 607–608 (2023). https://doi.org/10.1038/s41551-023-01042-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41551-023-01042-0
- Springer Nature Limited